SAGIA classifies Sadara as strategic

Updated 21 June 2015
0

SAGIA classifies Sadara as strategic

Sadara Chemical Company (Sadara) has been classified as strategic by the Saudi Arabian General Investment Authority (SAGIA), the governmental entity established to oversee investment affairs in the Kingdom of Saudi Arabia. This puts Sadara in the highest classification category achievable under SAGIA’s current investment rankings.
This classification of Sadara’s investment status is in recognition of its commitment to enhancing the value of its investments in the petrochemical and chemical sectors of Saudi Arabia. This is also recognition of Sadara’s success in bringing associated investments into the Kingdom, providing significant employment opportunities for Saudi nationals, and driving further development of the industry or associated industries, according to SAGIA.
“We are pleased to have achieved the highest ranking with SAGIA and their recognition of Sadara’s positive impact on the Saudi economy,” said Ziad Al-Labban, CEO of Sadara. “We are driven by the support tendered to us by our stakeholders, Saudi Aramco and The Dow Chemical Company, and are committed to continuing to contribute to the enhancement and strengthening of the Kingdom’s value creation opportunities.”
“I would also like to thank SAGIA for its support of Sadara and its active role in helping the project achieve the successes it has to date,” Al-Labban added.
The evaluation criteria included a detailed appraisal of various aspects of Sadara and its business. This includes the transfer and localization of technological knowledge, diversification of the Kingdom’s economy, increasing exports and decreasing imports; developing local human resources, reinforcing and boosting the economic competitiveness of local products in both domestic and international markets, and encouraging balanced development of the various regions of the Kingdom.


New J-Clinic to harness machine learning tech

Updated 25 September 2018
0

New J-Clinic to harness machine learning tech

MIT and Community Jameel, the social enterprise organization founded and chaired by Mohammed Abdul Latif Jameel ‘78, launched the Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic) on Tuesday. This is the fourth major collaborative effort between MIT and Community Jameel.
J-Clinic, a key part of the MIT Quest for Intelligence, will focus on developing machine learning technologies to revolutionize the prevention, detection, and treatment of disease. It will concentrate on creating and commercializing high-precision, affordable, and scalable machine learning technologies in areas of health care ranging from diagnostics to pharmaceuticals, with three main areas of focus:
l Preventative medicine methods and technologies with the potential to change the course of non-infectious disease by stopping it in its tracks.
l Cost-effective diagnostic tests that may be able to both detect and alleviate health problems.
l Drug discovery and development to enable faster and cheaper discovery, development, and manufacture of new pharmaceuticals, particularly those targeted for individually customized therapies.
J-Clinic’s holistic approach will utilize MIT’s expertise in cellular and medical biology, computer science, engineering, and the social sciences, among other areas.
“The health care system has no shortage of data,” said MIT President L. Rafael Reif. “But it has far too little access to the kinds of tools and experts who can translate population-level data into clinical insights that could make it possible to tune care precisely for individuals. Building on MIT’s deep expertise in fields from cancer to neuroscience, and our longstanding connections to Boston’s world-class medical community, J-Clinic offers an accelerated path to creating new technologies that could help make health care more effective everywhere — from villages in developing nations to major teaching hospitals.”
“The J-Clinic will positively impact the world by accelerating the creation of machine learning technologies and algorithms that will make preventing, detecting, and treating disease more precise, affordable, and personalized,” said Anantha P. Chandrakasan, dean of the MIT School of Engineering, and Vannevar Bush, professor of electrical engineering and computer science, who will serve as J-Clinic’s chair. “It will be a truly multifaceted effort that amplifies synergies between the life sciences and the latest research in human and machine intelligence. J-Clinic will inspire innovation for the betterment of humanity.”
“Channeling MIT’s machine learning expertise into health care will transform medical outcomes for people around the world,” said Fady Jameel, president of Community Jameel International. “Health care has been an important sphere of activity for Community Jameel since our earliest days, from founding the first nonprofit hospital for physical rehabilitation in Saudi Arabia, to partnering with the King Salman Center for Disability Research. J-Clinic continues our journey of supporting cutting-edge research and driving innovation in health care, in Saudi Arabia and around the whole world.”